A 70% Viral load reduction is a beacon of light. This appears to be a very big deal. Reposted from this link:
http://finance.yahoo.com/news/Power-of-the-Dream-Ventures-iw-3446903143.html?x=0&.v=1
BUDAPEST, HUNGARY--(Marketwire - 04/11/11) - Power of the Dream Ventures, Inc. (OTC.BB:PWRV - News), Hungary's premier technology acquisition and development company, is pleased to announce Genetic Immunity's Phase II trial results for the Company's Lead Product candidate called DermaVir, based on a previously announced agreement whereby Power of the Dream Ventures will issue communications for Genetic Immunity on a going forward basis.
DermaVir, the world's first topical dendritic cell-targeting HIV therapeutic vaccine candidate, employs nanotechnology to boost the patient's own immune responses and to kill HIV-infected cells. The goal of DermaVir immune boosting therapy is to decrease antiretroviral drug exposure while maintaining undetectable HIV-RNA levels and achieve a remission (functional cure) in HIV-infected patients.
In a randomized, placebo-controlled, dose-ranging Phase II study conducted in Hamburg, Germany, thirty-six HIV-infected individuals, not yet taking antiretroviral drugs, received one of three DermaVir doses, or the placebo, every six weeks. "The treatments were very well-tolerated and CD4+ cell counts did not decrease," explained the study's Principle Investigator, Jan van Lunzen, MD of the University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit. "At 24 weeks, the individuals' HIV viral loads were compared to their baseline values. A statistically significant reduction of 0.5 log10 copies/mL, a 70 percent reduction equivalent to that produced by several anti-HIV drugs, was seen in the cohort receiving 0.4 mg DermaVir vaccinations. Also in this group, HIV gag-specific precursor/memory T cells increased by 97 percent as the viral load decreased, a result not seen with antiretroviral drugs. Based upon our study the immune boosting and antiviral activity of DermaVir immunizations may provide a unique treatment approach for people with HIV/AIDS."
